Stephen Shuttleworth
Chief Tech/Sci/R&D Officer bei Nalo Therapeutics, Inc.
Profil
Stephen joined Samsara BioCapital as a Venture Partner in 2019.
He is a pharmaceutical scientist with over 25 years’ experience in the UK, US and Canada biotech industry, leading small molecule therapeutics research programs across multiple molecular targets, primarily in cancer, and also in immune-inflammation, metabolic disorders and infectious diseases.
Prior to Samsara, Stephen was CSO and Executive Director (2008-19) and joint COO/CSO/ED (2017-19) of Karus Therapeutics, UK, where he was also the founding scientist of the company’s PI3K-beta/delta and HDAC6 programs.
At Karus, he designed and directed the research and preclinical development of the two small molecule cancer therapeutics, KA2237 and KA2507, from concept to Phase I clinical trials.
Prior to Karus, he was Head of New Projects Development at Cancer Research UK in London.
Previously, Stephen was Director of Chemistry at Piramed Pharma, UK, where he directed the company’s pan-PI3K and PI3K-delta research programs, and where he designed and led the research and preclinical development of the pan-PI3K anti-cancer agent Pictilisib (PI-728/GDC-0941), which was partnered with Genentech; Piramed was subsequently acquired by Roche for $160M.
Prior to Piramed, Stephen was Associate Director, Chemistry at Tularik, South San Francisco, and, beforehand, Research Leader, Chemistry at BioChem Pharma, Quebec.
He began his industrial career at Chiroscience, UK.
He has published extensively in the literature, primarily in small molecule therapeutics R&D and in medicinal and synthetic organic chemistry, and has been an invited speaker at a number of international R&D conferences.
He is an inventor on 48 US patents, and on multiple patent applications.
Stephen received his BSc (Hons) and PhD in Chemistry from the University of Liverpool, and in 2007 was appointed a Fellow of the Royal Society of Chemistry
Aktive Positionen von Stephen Shuttleworth
| Unternehmen | Position | Beginn |
|---|---|---|
| The University of Manchester | Corporate Officer/Principal | 01.01.2014 |
Samsara Biocapital LLC
 Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Private Equity Investor | 01.01.2019 |
Nalo Therapeutics, Inc.
 Nalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders. | Chief Tech/Sci/R&D Officer | 01.10.2019 |
Autobahn Labs, Inc.
 Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | Consultant / Advisor | 01.01.2019 |
Ehemalige bekannte Positionen von Stephen Shuttleworth
| Unternehmen | Position | Ende |
|---|---|---|
Karus Therapeutics Ltd.
 Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Chief Tech/Sci/R&D Officer | 01.01.2020 |
Piramed Ltd.
 Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Corporate Officer/Principal | 01.01.2006 |
Tularik, Inc.
 Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01.01.2003 |
Hox Therapeutics Ltd.
 Hox Therapeutics Ltd. BiotechnologyHealth Technology Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK. | Director/Board Member | - |
Shire Canada, Inc.
 Shire Canada, Inc. Pharmaceuticals: MajorHealth Technology Shire Canada, Inc. develops and markets medicines. It focuses on attention deficit hyperactivity disorder (ADHD), rare diseases, as well as gastrointestinal and renal diseases. The firm develops treatments for genetic disorders known as rare or orphan diseases. The company was founded in 1986 and is headquartered in Saint-Laurent, Canada. | Corporate Officer/Principal | - |
Ausbildung von Stephen Shuttleworth
| The University of Liverpool | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AMGEN INC. | Health Technology |
| Private Unternehmen | 10 |
|---|---|
Tularik, Inc.
Tularik, Inc. Miscellaneous Commercial ServicesCommercial Services Tularik, Inc. is engaged in the discovery and development of a broad range of novel and superior orally available medicines that act through the regulation of gene expression. Tularik's scientific platform is focused on three therapeutic areas: cancer, inflammation and metabolic disease. The company was founded in 1991 and is headquartered in South San Francisco, CA. | Commercial Services |
Piramed Ltd.
Piramed Ltd. Miscellaneous Commercial ServicesCommercial Services PIramed Ltd. develops drugs, diagnostics, and other therapeutic products. It develops treatment for cancers which include proliferation, invasion, angiogenesis, and metastasis. The company was co-founded by Michael Waterfield, Peter Parker, and Paul Workman in 2003 and is headquartered in Slough, UK. | Commercial Services |
Celltech Chiroscience Plc
 Celltech Chiroscience Plc Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, Celltech Chiroscience Plc is a research-based pharmaceutical group. | Commercial Services |
Karus Therapeutics Ltd.
Karus Therapeutics Ltd. BiotechnologyHealth Technology Karus Therapeutics Ltd. provides therapies for treatment of cancer and inflammatory diseases. It offers HDAC6 and PI3K inhibitors for the treatment of cancer. The firm’s products in pipeline include KA-2237, KAR4000 Series and KAR3000 Series for the treatment of chronic inflammation, haematological malignancies, and solid tumours. The company was founded in July 2005 by Arasu Ganesan, Graham Keith Packham and Paul Townsend and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Cancer Research UK
 Cancer Research UK Miscellaneous Commercial ServicesCommercial Services Cancer Research UK provides cancer research services. It supports and undertakes research on the biology and causes of cancer and develops anti-cancer drugs. The firm also provides general information about cancer and types of treatments and funds projects that help patients cope with the side effects of cancer and its treatment. Its institute also operates an online portal CancerHelp UK that provides patient information. The company was founded in 2001 and is headquartered in London, the United Kingdom. | Commercial Services |
Shire Canada, Inc.
Shire Canada, Inc. Pharmaceuticals: MajorHealth Technology Shire Canada, Inc. develops and markets medicines. It focuses on attention deficit hyperactivity disorder (ADHD), rare diseases, as well as gastrointestinal and renal diseases. The firm develops treatments for genetic disorders known as rare or orphan diseases. The company was founded in 1986 and is headquartered in Saint-Laurent, Canada. | Health Technology |
Samsara Biocapital LLC
Samsara Biocapital LLC Investment ManagersFinance Samsara Biocapital LLC (Samsara Biocapital) is an independent venture capital firm founded in 2016 by Srinivas Akkaraju. The firm is headquartered in Palo Alto, California. | Finance |
Hox Therapeutics Ltd.
Hox Therapeutics Ltd. BiotechnologyHealth Technology Hox Therapeutics Ltd. develops therapeutics for cancer diseases based on the role of HOX genes. The private company is based in Guildford, UK. | Health Technology |
Autobahn Labs, Inc.
Autobahn Labs, Inc. Medical/Nursing ServicesHealth Services Autobahn Labs, Inc. is a virtual incubator that partners with research institutions to accelerate the advancement of early-stage drug discovery and development. The company is based in Palo Alto, CA. The organization invests intellectual, financial, and physical capital to efficiently move projects from feasibility to novel drug candidates. Autobahn Labs was created by Samsara Biocapital, Evotec, and KCK Ltd. | Health Services |
Nalo Therapeutics, Inc.
Nalo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nalo Therapeutics, Inc. is a company that focuses on developing therapeutics to address unmet needs in cancer. Nalo Therapeutics is based in Belmont, CA and the CEO of the company is Keith Wilson. The company targets oncogenic driver mutations and/or proteins that are often difficult to drug. The company was founded in 2017 and collaborates with UCSF scientific cofounders. | Health Technology |
